Related Experiment Video
Updated: Feb 5, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor
Andrea Vaupel1, Philipp Holzer1, Stephane Ferretti1
1Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
Abstract:
Small molecule inhibitors of the p53-MDM2 protein complex are under intense investigation in clinical trials as anti-cancer agents, including our first generation inhibitor NVP-CGM097. We recently described the rational design of a novel pyrazolopyrrolidinone core as a new lead structure and now we report on the synthesis and optimization of this to provide a highly potent lead compound. This new compound displayed excellent oral efficacy in our preclinical mechanistic in vivo model and marked a significant milestone towards the identification of our second generation clinical candidate NVP-HDM201.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Equivalence: In Vitro and In Vivo Bioequivalence
Drug Product Performance: In Vitro–In Vivo Correlation
Dipeptidyl Peptidase 4 Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

